IN8bio presents Phase I INB-200 glioblastoma study data at ASCO 2026
PUBT · 6d ago
Share
Listen to the news
- IN8bio scheduled new clinical data from its Phase I INB-200 study of gene-modified autologous gamma-delta T cells in newly diagnosed glioblastoma for presentation at ASCO on June 1, 2026.
- Data were not presented in this announcement; release is positioned as an update on progress from early-stage testing and clinical characterization.
- Company also flagged translational findings that it says support previously observed survival benefits in DeltEx DRI-treated glioblastoma patients, with a broader pipeline update set for its May 21, 2026 R&D Day.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605060800PRIMZONEFULLFEED9713468) on May 06, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved